Literature DB >> 20160529

Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies.

Warren D Rosenblum1.   

Abstract

Pulmonary hypertension is a rare disorder caused by vasoconstriction of the pulmonary arteries that leads to elevation of pulmonary vascular resistance, right ventricular failure, and ultimately death. Hypertrophy and proliferation of the pulmonary vascular endothelium leads to remodeling of this vascular system, resulting in a progressive disorder. In the past decade the molecular mechanisms and pathobiology of this disorder has become clearer. In addition, a host of new medical treatments and therapies are now available for what has been previously known to be a devastating disorder. Although much needs to be learned, this review will discuss our current knowledge, results of clinical trials, along with treatment options and emerging therapies available for the treatment of this disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160529     DOI: 10.1097/CRD.0b013e3181cd2c9e

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  6 in total

1.  Perinatal nitric oxide therapy prevents adverse effects of perinatal hypoxia on the adult pulmonary circulation.

Authors:  Anne-Christine Peyter; Flavien Delhaes; Giacomo Diaceri; Steeve Menétrey; Jean-François Tolsa
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

2.  MicroRNA‑138 promotes proliferation and suppresses mitochondrial depolarization in human pulmonary artery smooth muscle cells through targeting TASK‑1.

Authors:  Jin-Jun Liu; Heng Zhang; Fang Xing; Bi Tang; Shi-Li Wu; Ling Xuan; Pin-Fang Kang; Qiong Xu; Hong-Ju Wang; Ning-Ru Zhang; Xiao-Jing Wang
Journal:  Mol Med Rep       Date:  2017-12-06       Impact factor: 2.952

Review 3.  Chronic Thromboembolic Pulmonary Hypertension: An Update.

Authors:  Barbara Ruaro; Elisa Baratella; Gaetano Caforio; Paola Confalonieri; Barbara Wade; Cristina Marrocchio; Pietro Geri; Riccardo Pozzan; Alessia Giovanna Andrisano; Maria Assunta Cova; Maurizio Cortale; Marco Confalonieri; Francesco Salton
Journal:  Diagnostics (Basel)       Date:  2022-01-19

4.  Serotonin 2B receptor (5-HT2B R) signals through prostacyclin and PPAR-ß/δ in osteoblasts.

Authors:  Yasmine Chabbi-Achengli; Jean-Marie Launay; Luc Maroteaux; Marie Christine de Vernejoul; Corinne Collet
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

5.  Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.

Authors:  Abílio Reis; James Twiss; Margarida Vicente; Fabienne Gonçalves; Luísa Carvalho; José Meireles; Alzira Melo; Stephen P McKenna; Luís Almeida
Journal:  Health Qual Life Outcomes       Date:  2016-07-26       Impact factor: 3.186

6.  Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats.

Authors:  Fan Hu; Caijun Liu; Hanmin Liu; Liang Xie; Li Yu
Journal:  Med Sci Monit       Date:  2017-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.